First-line pembrolizumab plus chemotherapy may benefit patients with advanced biliary tract cancers

The addition of pembrolizumab (Keytruda) to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer, according to results from the phase III KEYNOTE-966 clinical trial, which were presented at the AACR Annual Meeting 2023, held April 14–19. The research is also published in The Lancet.